Research programme: biodefence bacterial vaccine - Syntiron
Latest Information Update: 28 Feb 2022
At a glance
- Originator Syntiron
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anthrax; Melioidosis; Plague
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Anthrax in USA (Parenteral)
- 28 Feb 2022 No recent reports of development identified for preclinical development in Melioidosis in USA (Parenteral)
- 28 Feb 2022 No recent reports of development identified for preclinical development in Plague in USA (Parenteral)